Skip to main content
OpenTrials
Completed

NCT Number: NCT07017790

Amino Acid PET to Assess the Efficacy of IDH Inhibitor Treatments for IDH Mutated Gliomas

Amino acid PET imaging could represent a biomarker for the evaluation of IDH inhibitor treatments for patients with refractory IDH-mutated gliomas

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Glioma Neoplasms Neoplasms by Histologic Type Neoplasms, Germ Cell and Embryonal Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue Neoplasms, Neuroepithelial Neuroectodermal Tumors

Age range

18 year–90 year

Sex eligibility

All sexes

Study type

Observational

Primary location

CHRU of NANCY

Vandœuvre-lès-Nancy, 54511, France

About this study

Amino acid PET imaging could represent a biomarker for the evaluation of IDH inhibitor treatments for patients with refractory IDH-mutated gliomas In fact, this study will allow us to assess, using Rano 1.0 criteria for PET and Rano 2.0 criteria for MRI, which of the two examinations is most effective in assessing the efficacy of anti-IDH treatment patients with refractory IDH-mutated gliomas.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients who underwent amino acid PET for early assessment of therapeutic response of IDH-mutated gliomas under anti-IDH treatment between February 2022 and November 2024

Exclusion criteria

  • Individuals who have objected to the use of their data

Treatment and study plan

Amino-acid PET

Other

Patients received 18-fluoroDopa then a PET exam

Primary outcomes

  1. Compare the performance between amino acid PET and brain MRI to assess a treatment efficacy

    Time frame: one day

    Comparison between early therapeutic response according to RANO 1.0 and RANO 2.0 PET criteria and tumor progression at 6 months

Secondary outcomes

  1. Compare the performance between amino acid PET and brain MRI to assess a treatment efficacy for the identification of lesions

    Time frame: one day

    Determination of the number of lesions assessable by amino acid PET according to RANO 1.0 PET criteria and by MRI according to RANO 2.0 criteria

Sponsors and collaborators

Lead sponsor

Central Hospital, Nancy, France

Other

Registry information

Official study title

Amino Acid PET Imaging to Assess the Efficacy of IDH Inhibitor Treatments for Patients With Refractory IDH Mutated Gliomas

Acronym: TEP-IDH

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Jun 12, 2025
Registry last updated
Jun 25, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.